Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 9;3(13):1926-1929.
doi: 10.1182/bloodadvances.2018025726.

Reducing Minimal Residual Disease With Blinatumomab Prior to HCT for Pediatric Patients With Acute Lymphoblastic Leukemia

Affiliations
Free PMC article

Reducing Minimal Residual Disease With Blinatumomab Prior to HCT for Pediatric Patients With Acute Lymphoblastic Leukemia

Amy K Keating et al. Blood Adv. .
Free PMC article

Abstract

Children treated with blinatumomab for B-ALL with MRD had few side effects and proceeded to hematopoietic cell transplant without delay.Blinatumomab given prior to transplant reduces MRD and results in favorable leukemia-free survival, toxicity, and overall survival.

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Post-HCT outcomes. (A) Cumulative incidence of relapse. (B) LFS. (C) OS.

Similar articles

See all similar articles

Cited by 2 articles

Feedback